M
Michael Naughton
Researcher at Washington University in St. Louis
Publications - 77
Citations - 4385
Michael Naughton is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 29, co-authored 76 publications receiving 3896 citations. Previous affiliations of Michael Naughton include University of Washington & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Shunqiang Li,Dong Shen,Jieya Shao,Robert J. Crowder,Wenbin Liu,Aleix Prat,Xiaping He,Shuying Liu,Jeremy Hoog,Charles Lu,Li Ding,Obi L. Griffith,Christopher A. Miller,Dave Larson,Robert S. Fulton,Michelle Harrison,Thomas B. Mooney,Joshua F. McMichael,Jingqin Luo,Yu Tao,Rodrigo Franco Gonçalves,Christopher E. Schlosberg,Jeffrey F. Hiken,Laila Saied,César Sánchez,Therese Giuntoli,Caroline Bumb,Crystal Cooper,R.T. Kitchens,Austin Lin,Chanpheng Phommaly,Sherri R. Davies,Jin Zhang,Megha Shyam Kavuri,Donna McEachern,Yiyu Dong,Cynthia X. Ma,Timothy J. Pluard,Michael Naughton,Ron Bose,Rama Suresh,Reida G. McDowell,Loren S. Michel,Rebecca Aft,William E. Gillanders,Katherine DeSchryver,Richard K. Wilson,Shaomeng Wang,Gordon B. Mills,Ana M. Gonzalez-Angulo,John R. Edwards,Christopher G. Maher,Charles M. Perou,Elaine R. Mardis,Matthew J. Ellis +54 more
TL;DR: Deep sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not observed in standard cell lines.
Journal ArticleDOI
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Kwok-K. Wong,Paula M. Fracasso,Ronald M. Bukowski,Thomas J. Lynch,Pamela N. Munster,Geoffrey I. Shapiro,Pasi A. Jänne,Joseph Paul Eder,Michael Naughton,Matthew J. Ellis,Suzanne F. Jones,Tarek Mekhail,Charles Zacharchuk,Jennifer Vermette,Richat Abbas,Susan Quinn,Christine Powell,Howard A. Burris +17 more
TL;DR: The maximum tolerated dose of once-daily oral Neratinib is 320 mg, and the pharmacokinetic profile of neratinib supports a once-a-day dosing regimen, warranting its further evaluation.
Journal ArticleDOI
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial
Rebecca Aft,Rebecca Aft,Michael Naughton,Kathryn Trinkaus,Mark A. Watson,Lourdes R. Ylagan,Mariana Chavez-MacGregor,Mariana Chavez-MacGregor,Jing Zhai,Sacha Kuo,William D. Shannon,Kathryn Diemer,Virginia Herrmann,Virginia Herrmann,Jill Dietz,Jill Dietz,Amjad Ali,Matthew J. Ellis,Peter Weiss,Timothy J. Eberlein,Cynthia X. Ma,Paula M. Fracasso,Paula M. Fracasso,Imran Zoberi,Marie E. Taylor,William E. Gillanders,Timothy J. Pluard,Joanne E. Mortimer,Katherine N. Weilbaecher +28 more
TL;DR: Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery, which supports the hypothesis that the antimetastatic effects of zoledronic Acid may be through effects on D TCs.
Journal ArticleDOI
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Cynthia X. Ma,Feng Gao,Jingqin Luo,Donald W. Northfelt,Matthew P. Goetz,Andres Forero,Jeremy Hoog,Michael Naughton,Foluso O. Ademuyiwa,Rama Suresh,Karen S. Anderson,Julie A. Margenthaler,Rebecca Aft,Timothy J. Hobday,Timothy J. Moynihan,William E. Gillanders,Amy E. Cyr,Timothy J. Eberlein,Tina J. Hieken,Helen Krontiras,Zhanfang Guo,Michelle V. Lee,Nicholas C. Spies,Zachary L. Skidmore,Obi L. Griffith,Malachi Griffith,Shana Thomas,Caroline Bumb,Kiran Vij,Cynthia Huang Bartlett,Maria Koehler,Hussam Al-Kateb,Souzan Sanati,Matthew J. Ellis +33 more
TL;DR: Palbociclib is an active antiproliferative agent for early-stage breast cancer resistant to anastrozole; however, prolonged administration may be necessary to maintain its effect.
Journal ArticleDOI
Symptom evaluation in palliative medicine: patient report vs systematic assessment
Jade Homsi,Declan Walsh,Nilo I. Rivera,Lisa Rybicki,Kristine A. Nelson,Susan B. LeGrand,Mellar P. Davis,Michael Naughton,Dragoslav Gvozdjan,Hahn Pham +9 more
TL;DR: The median number of symptoms found using systematic assessment was tenfold higher (p<0.001) than those volunteered and specific detailed symptom inquiry is essential for optimal palliation in advanced disease.